Cargando…

Mitochondria: A Therapeutic Target for Parkinson’s Disease?

Parkinson’s disease (PD) is one of the most common neurodegenerative disorders. The exact causes of neuronal damage are unknown, but mounting evidence indicates that mitochondrial-mediated pathways contribute to the underlying mechanisms of dopaminergic neuronal cell death both in PD patients and in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Yu, Hoffer, Alan, Hoffer, Barry, Qi, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613227/ https://www.ncbi.nlm.nih.gov/pubmed/26340618 http://dx.doi.org/10.3390/ijms160920704

Ejemplares similares

Inhibition of Drp1 mitochondrial translocation provides neural protection in dopaminergic system in a Parkinson’s disease model induced by MPTP
por: Filichia, Emily, et al.
Publicado: (2016)

Pathological and Therapeutic Advances in Parkinson’s Disease: Mitochondria in the Interplay
por: Naren, Padmashri, et al.
Publicado: (2023)

A New Treatment Strategy for Parkinson's Disease through the Gut–Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway
por: Kim, Dong Seok, et al.
Publicado: (2017)

Drug Repurposing in the Treatment of Traumatic Brain Injury
por: Ghiam, Michael K., et al.
Publicado: (2021)

Mitochondria-Targeted Protective Compounds in Parkinson's and Alzheimer's Diseases
por: Fernández-Moriano, Carlos, et al.
Publicado: (2015)

Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine
por: Hoffer, Barry J., et al.
Publicado: (2017)

Parenteral Nutrition: Amino Acids
por: Hoffer, Leonard John
Publicado: (2017)

Brain Mitochondria, Aging, and Parkinson’s Disease
por: Rango, Mario, et al.
Publicado: (2018)

Therapeutic Potential of Targeting Mitochondria for Alzheimer’s Disease Treatment
por: Atlante, Anna, et al.
Publicado: (2022)

Amelioration of Acute Sequelae of Blast Induced Mild Traumatic Brain Injury by N-Acetyl Cysteine: A Double-Blind, Placebo Controlled Study
por: Hoffer, Michael E., et al.
Publicado: (2013)

Mitochondria: a new therapeutic target in chronic kidney disease
por: Granata, Simona, et al.
Publicado: (2015)

Teaching the basics of repurposing mitochondria-targeted drugs: From Parkinson's disease to cancer and back to Parkinson's disease
por: Kalyanaraman, Balaraman
Publicado: (2020)

Parkinson's Disease: The Mitochondria-Iron Link
por: Muñoz, Yorka, et al.
Publicado: (2016)

ER–mitochondria signaling in Parkinson’s disease
por: Gómez-Suaga, Patricia, et al.
Publicado: (2018)

Are heat shock proteins therapeutic target for Parkinson's disease?
por: Luo, Guang-Rui, et al.
Publicado: (2006)

Targeting Mitochondria by Plant Secondary Metabolites: A Promising Strategy in Combating Parkinson’s Disease
por: Fakhri, Sajad, et al.
Publicado: (2021)

Mitochondria and Parkinson's Disease
por: Simon, David K., et al.
Publicado: (2011)

Delayed Dopamine Dysfunction and Motor Deficits in Female Parkinson Model Mice
por: Chen, Yuan-Hao, et al.
Publicado: (2019)

Intraocular lens power calculation in eyes with previous corneal refractive surgery
por: Savini, Giacomo, et al.
Publicado: (2018)

Nutrition in critical illness: a current conundrum
por: Hoffer, L. John, et al.
Publicado: (2016)

Mitochondria targeting nano agents in cancer therapeutics
por: Zhang, Xiao-Ying, et al.
Publicado: (2016)

Activation of stem cell up-regulation/mobilization: a cardiovascular risk in both mice and humans with implications for liver disease, psoriasis and SLE
por: Gemery, John M, et al.
Publicado: (2019)

The Role of Mitochondria-Derived Peptides in Cardiovascular Diseases and Their Potential as Therapeutic Targets
por: Dabravolski, Siarhei A., et al.
Publicado: (2021)

Mitochondria in Huntington’s disease: implications in pathogenesis and mitochondrial-targeted therapeutic strategies
por: Jurcau, Anamaria, et al.
Publicado: (2022)

Mitochondria as a therapeutic target in Alzheimer's disease
por: Wang, Jian, et al.
Publicado: (2016)

The ubiquitous role of mitochondria in Parkinson and other neurodegenerative diseases
por: Theocharopoulou, Georgia
Publicado: (2020)

Dysregulated Interorganellar Crosstalk of Mitochondria in the Pathogenesis of Parkinson’s Disease
por: Sironi, Lara, et al.
Publicado: (2020)

Mitochondria and Parkinson’s Disease: Clinical, Molecular, and Translational Aspects
por: Borsche, Max, et al.
Publicado: (2021)

Therapeutic targeting of mitophagy in Parkinson's disease
por: Masaldan, Shashank, et al.
Publicado: (2022)

IVth International Symposium on Neural Transplantation Transcript of the Closing Discussion (Edited) (Session 44.0)
por: Redmond Jr., D. Eugene, et al.
Publicado: (1993)

Minor Immunoreactivity in GDNF-, BDNF-, or NT-3-Treated Substantia Nigra Allografts
por: Shinoda, Masaki, et al.
Publicado: (1997)

Mitochondria-Targeted Antioxidants as a Therapeutic Strategy for Chronic Obstructive Pulmonary Disease
por: Fairley, Lauren H., et al.
Publicado: (2023)

Decreased Level of Nurr1 in Heterozygous Young Adult Mice Leads to Exacerbated Acute and Long-Term Toxicity after Repeated Methamphetamine Exposure
por: Luo, Yu, et al.
Publicado: (2010)

Targeting Mitochondria as Therapeutic Strategy for Metabolic Disorders
por: Sorriento, Daniela, et al.
Publicado: (2014)

PINK1: A Bridge between Mitochondria and Parkinson’s Disease
por: Gonçalves, Filipa Barroso, et al.
Publicado: (2021)

Mitochondria in the context of Parkinson's disease
por: Villacé, Patricia, et al.
Publicado: (2017)

Ceramide Metabolism and Parkinson’s Disease—Therapeutic Targets
por: Custodia, Antía, et al.
Publicado: (2021)

El verdadero creyente : Sobre el fanatismo y los movimientos sociales /
por: Hoffer, Eric
Publicado: (2009)

Exercise Ameliorates Motor Deficits and Improves Dopaminergic Functions in the Rat Hemi-Parkinson’s Model
por: Chen, Yuan-Hao, et al.
Publicado: (2018)

The Epigenome as a therapeutic target for Parkinson's disease
por: Hegarty, Shane V., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4hf4htsjm2504rk2uadpuig1is